The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 08, 2017

Filed:

Oct. 05, 2016
Applicant:

The Wistar Institute of Anatomy and Biology, Philadelphia, PA (US);

Inventors:

Jose R. Conejo-Garcia, Philadelphia, PA (US);

Michael Allegrezza, Philadelphia, PA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61P 35/00 (2006.01); A61P 35/04 (2006.01); A61K 38/20 (2006.01); A61K 38/17 (2006.01); A61K 31/519 (2006.01); A61K 31/506 (2006.01); A61K 31/397 (2006.01); A61K 31/4184 (2006.01); A61K 31/4458 (2006.01); A61K 31/437 (2006.01); A61K 31/145 (2006.01); C07K 14/54 (2006.01); C07K 14/715 (2006.01); C07D 471/04 (2006.01);
U.S. Cl.
CPC ...
A61K 38/2086 (2013.01); A61K 31/145 (2013.01); A61K 31/397 (2013.01); A61K 31/4184 (2013.01); A61K 31/437 (2013.01); A61K 31/4458 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 38/1793 (2013.01); A61K 38/2013 (2013.01); A61K 38/2046 (2013.01); C07D 471/04 (2013.01); C07K 14/5418 (2013.01); C07K 14/5443 (2013.01); C07K 14/7155 (2013.01);
Abstract

A method of treating a mammalian subject with cancer comprises administering to said subject having a cancer, e.g., a metastatic or refractory cancer or tumor, a small molecule inhibitor of a target signaling molecule of the MEK/MAPK pathway that impairs T cell activation, and administering to said subject a molecule that induces T cell proliferation in the presence of said inhibitor. The combination of a small molecule inhibitor of a target of the MEK/MAPK pathway and the T cell proliferation inducer reduces the proliferation of the cancer and tumor cells in vivo. Compositions and kits including these components are also provided.


Find Patent Forward Citations

Loading…